A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
Takeda
Seagen Inc.
Takeda
Seagen Inc.
National Cancer Institute (NCI)